Global Vaginal Fungi Infections Treatment Market
Global Vaginal Fungi Infections Treatment Market

Vaginal Fungi Infections Treatment Comprehensive Study by Type (Fluconazole, Nystatin, Flucytosine, Others), Route of Administration (Injection, Ointment, Oral), Distribution Channel (Online, Offline), By Infection (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis)

Vaginal Fungi Infections Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 201 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Vaginal Fungi Infections Treatment Market Scope?
A healthful vagina contains bacteria and few yeast cells, but when the balance of bacteria and yeast changes, the yeast cells can multiply, which further leads to intense itching, sore , and inflammation. A vaginal yeast infection is a fungal infection that causes irritation, discharge and intense itchiness of the vagina and the vulva the tissues at the vaginal opening. Vaginal fungi infections are identified by various symptoms such as swelling around the vagina, burning sensation during urination or sex, whitish-grey and clumpy vaginal discharge, and many others. Vaginal fungus infection is also known as candidiasis.

The Vaginal Fungi Infections Treatment market study is being classified by Type (Fluconazole, Nystatin, Flucytosine and Others) and major geographies with country level break-up.

The market examined is moderately competitive and there is a presence of nearby just as global organizations in the market considered. The significant organizations working in the market are focusing on item developments, extensions, finding new business sectors, or improving their center competency to extend their individual piece of the overall industry. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Vaginal Fungi Infections Treatment market throughout the predicted period.

Pfizer Inc. (United States), Bausch Health Companies Inc (Canada), ANI Pharmaceuticals, Inc. (United States), Hikma Pharmaceuticals Plc (United Kingdom), Lupin Limited (India), Mycovia Pharmaceuticals, Inc. (United States), Glenmark Pharmaceuticals Limited (India), PEPTONIC medical AB (Sweden), Aurobindo Pharma Limited (India), Dr. Reddy's Laboratories(India) and SCYNEXIS, Inc (United States) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Vaginal Fungi Infections Treatment market by Type, Application and Region.

On the basis of geography, the market of Vaginal Fungi Infections Treatment has been segmented into .

In July 2020 Cadila Pharma India-based pharmaceuticals company launches a drug for the treatment of Vulvovaginal Candidiasis named Fenticonazole Nitrate Vaginal Capsules under the brand name Fenticad.


Influencing Market Trend
  • Increasing acquisitions by key players

Market Drivers
  • Rising incidence of a vaginal fungi infection
  • Growing Awareness for Vaginal Fungi Infections Treatment

Opportunities
  • The increase in the number of patients affected by Vaginal Fungi Infections in the developing markets

Restraints
  • Increasing adoption of alternative therapies

Challenges
  • Competition from Herbal Medicines and Alternate Therapies


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Vaginal Fungi Infections Treatment Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Fluconazole
  • Nystatin
  • Flucytosine
  • Others
By Route of Administration
  • Injection
  • Ointment
  • Oral

By Distribution Channel
  • Online
  • Offline

By By Infection
  • Oral Candidiasis
  • Vulvovaginal Candidiasis
  • Cutaneous Candidiasis
  • Invasive Candidiasis
  • Systemic Candidiasis

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Rising incidence of a vaginal fungi infection
        • 3.2.2. Growing Awareness for Vaginal Fungi Infections Treatment
      • 3.3. Market Challenges
        • 3.3.1. Competition from Herbal Medicines and Alternate Therapies
      • 3.4. Market Trends
        • 3.4.1. Increasing acquisitions by key players
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Vaginal Fungi Infections Treatment, by Type, Route of Administration, Distribution Channel and By Infection (value, volume and price ) (2015-2020)
      • 5.1. Introduction
      • 5.2. Global Vaginal Fungi Infections Treatment (Value)
        • 5.2.1. Global Vaginal Fungi Infections Treatment by: Type (Value)
          • 5.2.1.1. Fluconazole
          • 5.2.1.2. Nystatin
          • 5.2.1.3. Flucytosine
          • 5.2.1.4. Others
        • 5.2.2. Global Vaginal Fungi Infections Treatment by: Route of Administration (Value)
          • 5.2.2.1. Injection
          • 5.2.2.2. Ointment
          • 5.2.2.3. Oral
        • 5.2.3. Global Vaginal Fungi Infections Treatment by: Distribution Channel (Value)
          • 5.2.3.1. Online
          • 5.2.3.2. Offline
      • 5.3. Global Vaginal Fungi Infections Treatment (Volume)
        • 5.3.1. Global Vaginal Fungi Infections Treatment by: Type (Volume)
          • 5.3.1.1. Fluconazole
          • 5.3.1.2. Nystatin
          • 5.3.1.3. Flucytosine
          • 5.3.1.4. Others
        • 5.3.2. Global Vaginal Fungi Infections Treatment by: Route of Administration (Volume)
          • 5.3.2.1. Injection
          • 5.3.2.2. Ointment
          • 5.3.2.3. Oral
        • 5.3.3. Global Vaginal Fungi Infections Treatment by: Distribution Channel (Volume)
          • 5.3.3.1. Online
          • 5.3.3.2. Offline
      • 5.4. Global Vaginal Fungi Infections Treatment (Price)
        • 5.4.1. Global Vaginal Fungi Infections Treatment by: Type (Price)
    • 6. Vaginal Fungi Infections Treatment: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2020)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Pfizer Inc. (United States)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. Bausch Health Companies Inc (Canada)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. ANI Pharmaceuticals, Inc. (United States)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Hikma Pharmaceuticals Plc (United Kingdom)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Lupin Limited (India)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Mycovia Pharmaceuticals, Inc. (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Glenmark Pharmaceuticals Limited (India)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. PEPTONIC medical AB (Sweden)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Aurobindo Pharma Limited (India)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Dr. Reddy's Laboratories(India)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
        • 6.4.11. SCYNEXIS, Inc (United States)
          • 6.4.11.1. Business Overview
          • 6.4.11.2. Products/Services Offerings
          • 6.4.11.3. Financial Analysis
          • 6.4.11.4. SWOT Analysis
    • 7. Global Vaginal Fungi Infections Treatment Sale, by Type, Route of Administration, Distribution Channel and By Infection (value, volume and price ) (2021-2026)
      • 7.1. Introduction
      • 7.2. Global Vaginal Fungi Infections Treatment (Value)
        • 7.2.1. Global Vaginal Fungi Infections Treatment by: Type (Value)
          • 7.2.1.1. Fluconazole
          • 7.2.1.2. Nystatin
          • 7.2.1.3. Flucytosine
          • 7.2.1.4. Others
        • 7.2.2. Global Vaginal Fungi Infections Treatment by: Route of Administration (Value)
          • 7.2.2.1. Injection
          • 7.2.2.2. Ointment
          • 7.2.2.3. Oral
        • 7.2.3. Global Vaginal Fungi Infections Treatment by: Distribution Channel (Value)
          • 7.2.3.1. Online
          • 7.2.3.2. Offline
      • 7.3. Global Vaginal Fungi Infections Treatment (Volume)
        • 7.3.1. Global Vaginal Fungi Infections Treatment by: Type (Volume)
          • 7.3.1.1. Fluconazole
          • 7.3.1.2. Nystatin
          • 7.3.1.3. Flucytosine
          • 7.3.1.4. Others
        • 7.3.2. Global Vaginal Fungi Infections Treatment by: Route of Administration (Volume)
          • 7.3.2.1. Injection
          • 7.3.2.2. Ointment
          • 7.3.2.3. Oral
        • 7.3.3. Global Vaginal Fungi Infections Treatment by: Distribution Channel (Volume)
          • 7.3.3.1. Online
          • 7.3.3.2. Offline
      • 7.4. Global Vaginal Fungi Infections Treatment (Price)
        • 7.4.1. Global Vaginal Fungi Infections Treatment by: Type (Price)
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Vaginal Fungi Infections Treatment: by Type(USD Million)
    • Table 2. Vaginal Fungi Infections Treatment: by Route of Administration(USD Million)
    • Table 3. Vaginal Fungi Infections Treatment: by Distribution Channel(USD Million)
    • Table 4. Vaginal Fungi Infections Treatment Sales: by Type(K Units)
    • Table 5. Vaginal Fungi Infections Treatment Sales: by Route of Administration(K Units)
    • Table 6. Vaginal Fungi Infections Treatment Sales: by Distribution Channel(K Units)
    • Table 7. Vaginal Fungi Infections Treatment: by Type(USD/Units)
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Company Basic Information, Sales Area and Its Competitors
    • Table 17. Company Basic Information, Sales Area and Its Competitors
    • Table 18. Company Basic Information, Sales Area and Its Competitors
    • Table 19. Vaginal Fungi Infections Treatment: by Type(USD Million)
    • Table 20. Vaginal Fungi Infections Treatment: by Route of Administration(USD Million)
    • Table 21. Vaginal Fungi Infections Treatment: by Distribution Channel(USD Million)
    • Table 22. Vaginal Fungi Infections Treatment Sales: by Type(K Units)
    • Table 23. Vaginal Fungi Infections Treatment Sales: by Route of Administration(K Units)
    • Table 24. Vaginal Fungi Infections Treatment Sales: by Distribution Channel(K Units)
    • Table 25. Vaginal Fungi Infections Treatment: by Type(USD/Units)
    • Table 26. Research Programs/Design for This Report
    • Table 27. Key Data Information from Secondary Sources
    • Table 28. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Vaginal Fungi Infections Treatment: by Type USD Million (2015-2020)
    • Figure 5. Global Vaginal Fungi Infections Treatment: by Route of Administration USD Million (2015-2020)
    • Figure 6. Global Vaginal Fungi Infections Treatment: by Distribution Channel USD Million (2015-2020)
    • Figure 7. Global Vaginal Fungi Infections Treatment: by Type K Units (2015-2020)
    • Figure 8. Global Vaginal Fungi Infections Treatment: by Route of Administration K Units (2015-2020)
    • Figure 9. Global Vaginal Fungi Infections Treatment: by Distribution Channel K Units (2015-2020)
    • Figure 10. Global Vaginal Fungi Infections Treatment: by Type USD/Units (2015-2020)
    • Figure 11. Global Vaginal Fungi Infections Treatment share by Players 2020 (%)
    • Figure 12. Global Vaginal Fungi Infections Treatment share by Players (Top 3) 2020(%)
    • Figure 13. Global Vaginal Fungi Infections Treatment share by Players (Top 5) 2020(%)
    • Figure 14. BCG Matrix for key Companies
    • Figure 15. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 16. Pfizer Inc. (United States) Revenue: by Geography 2020
    • Figure 17. Bausch Health Companies Inc (Canada) Revenue, Net Income and Gross profit
    • Figure 18. Bausch Health Companies Inc (Canada) Revenue: by Geography 2020
    • Figure 19. ANI Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 20. ANI Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
    • Figure 21. Hikma Pharmaceuticals Plc (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 22. Hikma Pharmaceuticals Plc (United Kingdom) Revenue: by Geography 2020
    • Figure 23. Lupin Limited (India) Revenue, Net Income and Gross profit
    • Figure 24. Lupin Limited (India) Revenue: by Geography 2020
    • Figure 25. Mycovia Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 26. Mycovia Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
    • Figure 27. Glenmark Pharmaceuticals Limited (India) Revenue, Net Income and Gross profit
    • Figure 28. Glenmark Pharmaceuticals Limited (India) Revenue: by Geography 2020
    • Figure 29. PEPTONIC medical AB (Sweden) Revenue, Net Income and Gross profit
    • Figure 30. PEPTONIC medical AB (Sweden) Revenue: by Geography 2020
    • Figure 31. Aurobindo Pharma Limited (India) Revenue, Net Income and Gross profit
    • Figure 32. Aurobindo Pharma Limited (India) Revenue: by Geography 2020
    • Figure 33. Dr. Reddy's Laboratories(India) Revenue, Net Income and Gross profit
    • Figure 34. Dr. Reddy's Laboratories(India) Revenue: by Geography 2020
    • Figure 35. SCYNEXIS, Inc (United States) Revenue, Net Income and Gross profit
    • Figure 36. SCYNEXIS, Inc (United States) Revenue: by Geography 2020
    • Figure 37. Global Vaginal Fungi Infections Treatment: by Type USD Million (2021-2026)
    • Figure 38. Global Vaginal Fungi Infections Treatment: by Route of Administration USD Million (2021-2026)
    • Figure 39. Global Vaginal Fungi Infections Treatment: by Distribution Channel USD Million (2021-2026)
    • Figure 40. Global Vaginal Fungi Infections Treatment: by Type K Units (2021-2026)
    • Figure 41. Global Vaginal Fungi Infections Treatment: by Route of Administration K Units (2021-2026)
    • Figure 42. Global Vaginal Fungi Infections Treatment: by Distribution Channel K Units (2021-2026)
    • Figure 43. Global Vaginal Fungi Infections Treatment: by Type USD/Units (2021-2026)
    Some of the key companies/manufacturers profiled in the report
    • Pfizer Inc. (United States)
    • Bausch Health Companies Inc (Canada)
    • ANI Pharmaceuticals, Inc. (United States)
    • Hikma Pharmaceuticals Plc (United Kingdom)
    • Lupin Limited (India)
    • Mycovia Pharmaceuticals, Inc. (United States)
    • Glenmark Pharmaceuticals Limited (India)
    • PEPTONIC medical AB (Sweden)
    • Aurobindo Pharma Limited (India)
    • Dr. Reddy's Laboratories(India)
    • SCYNEXIS, Inc (United States)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation